Press release content from PR Newswire. The AP news staff was not involved in its creation.
LexisNexis® Risk Solutions and Accuity Merge Operations to Create One of the Largest Global Providers of Financial Crime Compliance Solutions
February 17, 2021 GMT
LexisNexis Risk Solutions (PRNewsfoto/LexisNexis Risk Solutions)
ATLANTA, Feb. 17, 2021 /PRNewswire/ Accuity and LexisNexis Risk Solutions announced they are merging operations. Both businesses are RELX companies and leaders in their respective focus areas in the global financial crime compliance sector with complementary solutions. Accuity is part of the LexisNexis Risk Solutions group of companies (LexisNexis Risk Solutions Group). The companies operate in more than 100 countries.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
AcuityAds Announces Date for Fourth Quarter and Full Year 2020 Financial Results Video Conference Call
February 17, 2021 GMT
TORONTO and NEW YORK, Feb. 17, 2021 /PRNewswire/ - AcuityAds Holdings Inc. (TSX: AT) (“AcuityAds” or “Company”), the leading technology company that enables advertisers to connect intelligently with audiences across digital advertising campaigns from a single platform, is pleased to announce that it will report its fourth quarter and full year 2020 financial results before market open on Tuesday, March 2nd, 2021.
The company will host a live video Zoom webcast to discuss the results on Tuesday, March 2nd, 2021 at 8:30am Eastern Time. The Zoom webcast will be hosted by Tal Hayek, Co-Founder and Chief Executive Officer, and Jonathan Pollack, Chief Financial Officer, with a question and answer session to follow.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery .
Progenity, Inc.February 17, 2021 GMT
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced the initiation of a clinical study for their Drug Delivery System (DDS) capsule, an ingestible and self-guided drug delivery device. The study will evaluate the capsule’s safety and tolerability in the gastrointestinal (GI) tract of Normal Healthy Volunteers (NHV). The study will also collect the first clinical data on the ability of the DDS to auto-locate and accurately deliver a payload to the colon, a key delivery site for the treatment of ulcerative colitis.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
CleanSpark Launches mVoult, a Direct-to-Consumer Residential Microgrid Solution
February 17, 2021 GMT
CleanSpark, Inc. Logo (PRNewsfoto/CleanSpark, Inc.)
SALT LAKE CITY, Feb. 17, 2021 /PRNewswire/ CleanSpark, Inc. (Nasdaq: CLSK) (the “Company” or “CleanSpark”), a diversified software and services company, today announced the launch of mVoult ( mvoult.com ) for home microgrids. mVoult is a standalone energy management controller that is capable of directing the operations of both existing and new energy assets. mVoult will be offered as a smart controller and mobile app specifically designed for residential applications. The Company also plans to launch a fully integrated mVoult branded battery energy storage and controls solution. The home power solution will enable the selection of optional add-ons such as solar integration or back-up generators. The systems are expected to cont
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of .
Ultragenyx Pharmaceutical Inc.February 17, 2021 GMT
NOVATO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Health Canada has approved Dojolvi™ (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD). Long-chain fatty acid oxidation disorders (LC-FAOD) are a group of rare, genetic, life-threatening disorders caused by defects in the enzymes needed to produce energy from fatty acids. Dojolvi is a highly purified, synthetic, 7-carbon fatty acid triglyceride specifically designed to pro